- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06372860
Estudo de Viabilidade DPP de Amamentação - eMOMS 2.0
Estudo de Viabilidade do Programa de Prevenção de Diabetes de Amamentação - Monitoramento Eletrônico da Agenda da Mamãe 2.0
The purpose of this study is to investigate the impact of a comprehensive intervention that combines breastfeeding support with a diabetes prevention-based program (DPP) on postpartum weight retention and lactation duration among women with pre-pregnancy overweight or obesity. This intervention, named eMOMS, is delivered by a certified health coach via a mobile health (mHealth) application.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study is a randomized controlled trial designed to determine the feasibility and efficacy of a combined breastfeeding, diabetes prevention-based program (DPP) in a cohort of overweight or obese women to be followed during pregnancy through 3 months postpartum. The trial will have two study arms: DPP + breastfeeding (Tx1) and Usual Care (Tx2).
Aim 1: Measure weight loss and duration of lactation through 3 months postpartum among target population. To accomplish this, we will measure pre-pregnancy weight, weight at study entry, weight immediately prior to and after delivery, and weight at specific postpartum time points. Lactation and infant feeding practices will be measured at similar postpartum time points. Aim 2: Quantify interest in use of the DPP-lactation mobile health (mHealth) application among target population. To accomplish this, we will: (1) measure research engagement including rates of screening and recruitment among users, especially rural and racially/ethnically diverse women; and (2) evaluate intervention uptake, delivery, and adherence via tracking/measuring use of the mHealth app.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67218
- Via Christi Maternal Fetal Medicine Clinic
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Pregnant
- In second trimester or early third trimester
- BMI >/= 25 and < 35
- At least 18 years old or older
- Able to read and understand English
- Able to learn and use a video platform
Exclusion Criteria:
- Complications related to pregnancy that require emergency care
- Thyroid disease
- Multiple gestation
- Substance abuse within last 3 years
- Assisted reproductive technology (ART)-related pregnancy
- Current smoker
- Prior bariatric surgery
- In weight-loss program within 3 months of conception
- BMI >/= 35
- Unable to attend intervention/ follow-up visits
- Unwilling to self-monitor data collection
- Unable to complete intervention
- Presence of any condition that limits walking
- Presence of any condition that limits following diet recommendations
- Pregnancies complicated with fetuses diagnosed with lethal malformations/conditions
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: DPP + Breastfeeding (Tx1)
Patients randomized to Tx1 will receive education in the Diabetes Prevention Program (DPP) and intensive breastfeeding education and support. Ante- and postpartum education includes access to the mHealth app and individualized 1-on-1 health coaching. Phase I is delivered antepartum and includes: four (4) 1-hour DPP-based educational sessions and six (6) 20-minute educational videos on lactation. Phase II is delivered postpartum and includes: in-hospital lactation support and two (2) 1-hour DPP-based educational sessions. Participants will continue to receive individualized 1-on-1 health coaching through 3 months postpartum. |
The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences. Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences. Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC). Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants. Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital. |
|
Comparador de Placebo: Usual Care
Usual care is described as obstetrical care that pregnant women with normal BMI receive and that is provided by their provider. There will not be any antepartum education or 1-on-1 health coaching. Postpartum education will only include usual care in-hospital lactation support. There will not be any other education nor 1-on-1 support. |
Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Weight
Prazo: At baseline and at delivery through 3 months postpartum
|
The study team measured maternal weight at baseline, at delivery, and at 3 months postpartum to allow for meaningful comparisons of weight change among study arms. |
At baseline and at delivery through 3 months postpartum
|
|
Maternal Weight
Prazo: At baseline and at delivery through 3 months postpartum
|
The study team measured maternal weight at baseline, at delivery, and at 3 months postpartum to allow for meaningful comparisons of weight change among study arms. |
At baseline and at delivery through 3 months postpartum
|
|
Duration of Breastfeeding and Supplementation
Prazo: At day 3, week 6, and 3 months postpartum.
|
The study team measured duration of breastfeeding and supplementation at day 3 postpartum and at specific timepoints through 3 months postpartum. Breastfeeding is defined as the feeding of human milk. The definition of "Exclusive Breastfeeding" is aligned with the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) and is as follows: the infant is fed only human milk and no other foods or fluids, not even water, except for oral rehydration solutions or drops/syrups of vitamins, minerals, or medicines. "Any Breastfeeding" is defined as the feeding of human milk supplemented with formula, water, etc. "Formula Only" is defined as the feeding of formula exclusively and no human milk. |
At day 3, week 6, and 3 months postpartum.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Enrollment
Prazo: This will occur between day 1 of the first participant screened to the study participant being randomized to one of two study arms.
|
To assess recruitment and enrollment rates, the study team tracked the number of potential participants contacted/screened versus the number of participants who were eligible to enroll and the number of participants who consented to enroll in the study. |
This will occur between day 1 of the first participant screened to the study participant being randomized to one of two study arms.
|
|
mHealth Application Engagement
Prazo: At 3 months postpartum.
|
To assess intervention uptake, the study team tracked the number of calls engaging with the mobile health app and with the health coach. |
At 3 months postpartum.
|
|
mHealth Application Engagement (2)
Prazo: At 3 months postpartum.
|
To assess intervention uptake, the study team tracked the amount of time spent engaging with the mobile health app and with the health coach. |
At 3 months postpartum.
|
|
mHealth Application Usage
Prazo: At 3 months postpartum.
|
To assess intervention usage, the study team tracked logged tasks into the mobile health app. |
At 3 months postpartum.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lisette Jacobson, PhD, MPA, MA, University of Kansas Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Distúrbios Nutricionais
- Doenças Metabólicas
- Supernutrição
- Peso corporal
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Condições Patológicas, Sinais e Sintomas
- Comportamento
- Doenças Nutricionais e Metabólicas
- Sinais e sintomas
- Comportamento Alimentar
- Excesso de peso
- Obesidade
- Estado pré-diabético
- Amamentação
- Fenômenos fisiológicos reprodutivos
- Fenômenos fisiológicos reprodutivos e urinários
- Período Pós-Parto
- Lactação
Outros números de identificação do estudo
- RKS2018350
- 3P20GM144269-02S2 (Concessão/Contrato do NIH dos EUA)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .